<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR26">
 <label>26.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Cascone</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>William</surname>
    <given-names>WN</given-names>
   </name>
   <name>
    <surname>Weissferdt</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Lin</surname>
    <given-names>HY</given-names>
   </name>
   <name>
    <surname>Leung</surname>
    <given-names>CH</given-names>
   </name>
   <name>
    <surname>Carter</surname>
    <given-names>BW</given-names>
   </name>
   <name>
    <surname>Fossella</surname>
    <given-names>FV</given-names>
   </name>
   <name>
    <surname>Mott</surname>
    <given-names>F</given-names>
   </name>
   <name>
    <surname>Papadimitrakopoulou</surname>
    <given-names>V</given-names>
   </name>
   <name>
    <surname>Blumenschein</surname>
    <given-names>GR</given-names>
    <suffix>Jr</suffix>
   </name>
   <name>
    <surname>le</surname>
    <given-names>X</given-names>
   </name>
   <name>
    <surname>Federico</surname>
    <given-names>L</given-names>
   </name>
   <name>
    <surname>Parra Cuentas</surname>
    <given-names>ER</given-names>
   </name>
   <name>
    <surname>Bernatchez</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Wistuba</surname>
    <given-names>II</given-names>
   </name>
   <name>
    <surname>Vaporciyan</surname>
    <given-names>AA</given-names>
   </name>
   <name>
    <surname>Gibbons</surname>
    <given-names>DL</given-names>
   </name>
   <name>
    <surname>Swisher</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Heymach</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Sepesi</surname>
    <given-names>B</given-names>
   </name>
   <collab>NEOSTAR Study Group</collab>
  </person-group>
  <article-title>Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): clinical and correlative results from the NEOSTAR study</article-title>
  <source>J Clin Oncol</source>
  <year>2019</year>
  <volume>37</volume>
  <issue>15_suppl</issue>
  <fpage>8504</fpage>
  <pub-id pub-id-type="doi">10.1200/JCO.2019.37.15_suppl.8504</pub-id>
 </element-citation>
</ref>
